Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Prostatic Neoplasms 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hereditary Breast and Ovarian Cancer Syndrome 1Breast Neoplasms 1

Interventions

Cytarabine 85Cyclophosphamide 58Azacitidine 57fludarabine 52venetoclax 41fludarabine phosphate 41Busulfan 30Filgrastim 23Whole-Body Irradiation 22Decitabine 21Mycophenolic Acid 20Methotrexate 19Mitoxantrone 18Etoposide 18Antilymphocyte Serum 18Cyclosporine 17Clofarabine 17Tacrolimus 16Granulocyte Colony-Stimulating Factor 16Peripheral Blood Stem Cell Transplantation 15Daunorubicin 15Melphalan 13thymoglobulin 11Thiotepa 11Stem Cell Transplantation 11Interleukin-2 11Idarubicin 10Gemtuzumab 9Cord Blood Stem Cell Transplantation 9aldesleukin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Myeloid, Acute × prexasertib × Clear all
NCT03735446 2019-06-12

Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

Dana-Farber Cancer Institute

Phase 1 Terminated
2 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡